Adma Biologics, Inc. (ADMA) Stock Analysis and Metrics

Adma Biologics

NASDAQ: ADMA

$8.28 ▼ -0.09 (-1.08%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.98 Bn

P/E-55.33

P/S3.87

Div. Yield0.00

ROIC (Qtr)-18,236.12

Total Debt (Qtr)72.14 Mn

Revenue Growth (1y) (Qtr)18.39

Add ratio to table…

About

ADMA Biologics Inc is a U. S. based end to end commercial biopharmaceutical company dedicated to manufacturing marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company focuses on immune globulin products derived from human plasma. Its operations span plasma collection fractionation purification and fill finish activities.

Revenue is derived primarily from the sale of three FDA approved immune globulin products ASCENIV BIVIGAM and Nabi HB which are used to treat primary immunodeficiency and hepatitis B exposure. The company also generates income from the sale of source plasma collected at its owned centers to third party manufacturers and from contract manufacturing and laboratory services provided to external clients. These revenue streams benefit from the company's control over both plasma supply and production processes.

The company operates through the following segments.

• The ADMA BioManufacturing segment is responsible for the fractionation purification and fill finish of immune globulin products including ASCENIV BIVIGAM and Nabi HB and for the development of pipeline candidates such as the S pneumonia hyperimmune globulin SG 001. This segment utilizes the Boca Raton Florida facility which has a peak annual processing capacity of up to six hundred thousand liters of plasma and has implemented a yield enhancement process that increases production output by twenty percent or more from the same source plasma volume. The segment also pursues label expansions for ASCENIV to include pediatric patients and conducts animal studies for SG 001 with plans to submit a pre IND package to the FDA in fiscal year 2026.

• The Plasma Collection Centers segment operates FDA licensed source plasma collection facilities that supply raw material for manufacturing and sell excess plasma to third party customers. As of year end 2025 the segment ran ten collection centers across the United States each capable of collecting thirty thousand to fifty thousand liters of source plasma annually and after a planned divestiture will retain seven centers. The segment also holds approvals from the Korean Ministry of Food and Drug Safety for certain centers and maintains authorization to run a hepatitis B immunization program.

ADMA Biologics Inc occupies a niche within the broader plasma products industry as a vertically integrated producer that controls both plasma collection and manufacturing. Its main competitors include large multinational firms such as CSL Behring Grifols Takeda Octapharma and BPL Kedrion. The company differentiates itself through proprietary donor screening methods that identify high titer plasma and through its in house fill finish capability which reduces reliance on external vendors. Recent yield enhancement initiatives and expanded four thousand four hundred liter production scales have improved gross margins and increased plant efficiency. These factors give ADMA a cost advantage and support sustained margin expansion as demand for immune globulin therapies grows.

The company sells its products to physician specialists hospitals infusion centers and specialty pharmacies through a network of national distributors and wholesalers. Major customers for the year ended 2025 were BioCare Inc and Priority Healthcare Distribution Inc doing business as CuraScript which together accounted for approximately seventy three percent of consolidated revenue. Additional revenue comes from third party plasma sales to other manufacturers and from contract service arrangements with various biopharmaceutical clients.

Investment Thesis

▲ Bull case

ADMA Biologics is positioned for accelerated growth driven by record ASCENIV demand that remains insulated from competitive pressures in the standard IG space, with Q1 2026 showing 28% year-over-year revenue growth and record metrics in new patient starts, prescriber adoption, product pull-through, and patient adherence, despite flat total revenue due to BIVIGAM headwinds, indicating underlying demand strength is being masked by temporary distribution dynamics and inventory recalibration rather than fundamental weakness, as evidenced by April utilization running in line with Q1 direct sales and signaling a reversion to normalized ordering patterns in the back half of the year.
The company’s monetization of three plasma centers and addition of a new third-party plasma supplier have enhanced liquidity while diversifying sourcing, ensuring ample high-titer plasma supply to support ASCENIV’s near- and long-term growth objectives, with pro forma net leverage below 0.5x and $100 million of additional borrowing capacity providing financial flexibility to fund capital allocation priorities including R&D investment in SG-01 without compromising balance sheet strength or cash generation, which reached $58 million in operating cash flow during Q1 2026.
ADMA’s yield enhancement manufacturing process creates a structural cost advantage by maximizing value from high-titer plasma collections, directly supporting both ASCENIV production efficiency and the development of SG-01, which targets a $300 million to $500 million annual peak market opportunity and leverages existing platform infrastructure for rapid commercialization if approved, with preclinical data already showing strong proof of concept for two prevalent pneumonia serotypes and a pre-IND package expected later in 2026, positioning SG-01 as a near-term catalyst that could unlock significant upside beyond current consensus estimates.
The shift in IG market dynamics toward oversupply and normalized supply/demand balance represents a long-term structural improvement for ADMA, as the company’s historical disadvantage during periods of undersupply is reversing, allowing its differentiated product ASCENIV to compete on clinical merits rather than allocation constraints, with management noting that IG growth has slowed to low single digits (2%-4%) but remains durable, and that ADMA is strategically targeting the secondary immune deficient population—the largest driver of IG growth—through its McKesson specialty distribution agreement, which is already contributing to net-new prescriber acquisition and utilization growth in April 2026.
Real-world evidence demonstrating ASCENIV’s ability to reduce hospitalizations, ER visits, and concomitant medications in refractory immunodeficient patients is strengthening payer and physician confidence, particularly in the buy-and-bill IVIG setting, with ADMA actively leveraging third-party publications and its own data to convert fence-sitting clinicians and expand formulary access, including discussions with pediatric teaching hospitals for hospitalized immunocompromised children following the pediatric label expansion, which creates a durable growth runway independent of near-term pricing volatility in standard IG products.

ADMA Biologics is positioned for accelerated growth driven by record ASCENIV demand that remains insulated from competitive pressures in the standard IG space, with Q1 2026 showing 28% year-over-year revenue growth and record metrics in new patient starts, prescriber adoption, product pull-through, and patient adherence, despite flat total revenue due to BIVIGAM headwinds, indicating underlying demand strength is being masked by temporary distribution dynamics and inventory recalibration rather than fundamental weakness, as evidenced by April utilization running in line with Q1 direct sales and signaling a reversion to normalized ordering patterns in the back half of the year.
The company’s monetization of three plasma centers and addition of a new third-party plasma supplier have enhanced liquidity while diversifying sourcing, ensuring ample high-titer plasma supply to support ASCENIV’s near- and long-term growth objectives, with pro forma net leverage below 0.5x and $100 million of additional borrowing capacity providing financial flexibility to fund capital allocation priorities including R&D investment in SG-01 without compromising balance sheet strength or cash generation, which reached $58 million in operating cash flow during Q1 2026.
ADMA’s yield enhancement manufacturing process creates a structural cost advantage by maximizing value from high-titer plasma collections, directly supporting both ASCENIV production efficiency and the development of SG-01, which targets a $300 million to $500 million annual peak market opportunity and leverages existing platform infrastructure for rapid commercialization if approved, with preclinical data already showing strong proof of concept for two prevalent pneumonia serotypes and a pre-IND package expected later in 2026, positioning SG-01 as a near-term catalyst that could unlock significant upside beyond current consensus estimates.
The shift in IG market dynamics toward oversupply and normalized supply/demand balance represents a long-term structural improvement for ADMA, as the company’s historical disadvantage during periods of undersupply is reversing, allowing its differentiated product ASCENIV to compete on clinical merits rather than allocation constraints, with management noting that IG growth has slowed to low single digits (2%-4%) but remains durable, and that ADMA is strategically targeting the secondary immune deficient population—the largest driver of IG growth—through its McKesson specialty distribution agreement, which is already contributing to net-new prescriber acquisition and utilization growth in April 2026.
Real-world evidence demonstrating ASCENIV’s ability to reduce hospitalizations, ER visits, and concomitant medications in refractory immunodeficient patients is strengthening payer and physician confidence, particularly in the buy-and-bill IVIG setting, with ADMA actively leveraging third-party publications and its own data to convert fence-sitting clinicians and expand formulary access, including discussions with pediatric teaching hospitals for hospitalized immunocompromised children following the pediatric label expansion, which creates a durable growth runway independent of near-term pricing volatility in standard IG products.

▼ Bear case

ADMA Biologics faces persistent and potentially prolonged competitive pressures in the standard IG space, with BIVIGAM revenue down 54% year-over-year in Q1 2026 due to aggressive discounting and rebating from new entrants who have eroded ASPs by 15% to 20% from launch levels, and management’s admission that they “never wanted to be in the standard IG business” raises concerns about strategic commitment to this franchise, which still contributes meaningfully to revenue and may require ongoing operational investment despite limited pricing power, creating a drag on overall profitability and diverting focus from higher-margin opportunities.
The company’s reliance on distribution normalization to improve DSOs and revenue visibility introduces execution risk, as Q1 2026 DSOs rose to 107 days—above the target range of 90–105 days—with improvement contingent on ordering patterns normalizing and the McKesson specialty agreement ramping up, both of which remain uncertain given ongoing channel dislocations and the lack of a clear timeline for when competitive pressures in standard IG will dissipate, potentially prolonging working capital strain and delaying cash flow conversion even as operating cash generation remains strong.
While ASCENIV demand remains strong, the revised full-year 2026 revenue guidance of $530 million to $560 million reflects only modest growth from the $458 million trailing twelve-month revenue as of Q1 2026, implying that the market may be overestimating the pace of ASCENIV’s penetration and the company’s ability to offset BIVIGAM declines, especially if standard IG competitive pressures persist beyond 2026 or if payer reimbursement environments tighten despite favorable real-world evidence, limiting upside to the current guidance range.
The SG-01 pipeline program, while highlighted as a potential $300 million to $500 million opportunity, remains in early preclinical stages with no clinical timelines provided, and management’s admission that they have not yet given timelines for clinical development—citing the need for a pre-IND meeting with the FDA later in 2026 to inform 2027 trial planning—suggests a longer path to market than implied by optimistic projections, with typical AIDP/PIDD studies requiring approximately 18 months to complete, meaning SG-01 is unlikely to contribute meaningfully to revenue before 2029 at the earliest, making it a distant catalyst that does not justify near-term valuation multiples.
ADMA’s gross margin expansion to 71% in Q1 2026, while impressive, is partly driven by the revenue mix shift toward higher-margin ASCENIV and cost savings from plasma center monetizations, which are one-time in nature; sustained margin expansion will depend on continued ASCENIV growth and yield enhancement benefits, but if BIVIGAM underperformance persists or if ASCENIV faces unexpected pricing pressure—despite management’s confidence in its insulation—the company may struggle to maintain margin momentum, particularly as operating expenses are expected to step up due to R&D spend on SG-01 and SG&A investments in commercial operations, potentially pressuring adjusted net income growth despite strong cash flow generation.

ADMA Biologics faces persistent and potentially prolonged competitive pressures in the standard IG space, with BIVIGAM revenue down 54% year-over-year in Q1 2026 due to aggressive discounting and rebating from new entrants who have eroded ASPs by 15% to 20% from launch levels, and management’s admission that they “never wanted to be in the standard IG business” raises concerns about strategic commitment to this franchise, which still contributes meaningfully to revenue and may require ongoing operational investment despite limited pricing power, creating a drag on overall profitability and diverting focus from higher-margin opportunities.
The company’s reliance on distribution normalization to improve DSOs and revenue visibility introduces execution risk, as Q1 2026 DSOs rose to 107 days—above the target range of 90–105 days—with improvement contingent on ordering patterns normalizing and the McKesson specialty agreement ramping up, both of which remain uncertain given ongoing channel dislocations and the lack of a clear timeline for when competitive pressures in standard IG will dissipate, potentially prolonging working capital strain and delaying cash flow conversion even as operating cash generation remains strong.
While ASCENIV demand remains strong, the revised full-year 2026 revenue guidance of $530 million to $560 million reflects only modest growth from the $458 million trailing twelve-month revenue as of Q1 2026, implying that the market may be overestimating the pace of ASCENIV’s penetration and the company’s ability to offset BIVIGAM declines, especially if standard IG competitive pressures persist beyond 2026 or if payer reimbursement environments tighten despite favorable real-world evidence, limiting upside to the current guidance range.
The SG-01 pipeline program, while highlighted as a potential $300 million to $500 million opportunity, remains in early preclinical stages with no clinical timelines provided, and management’s admission that they have not yet given timelines for clinical development—citing the need for a pre-IND meeting with the FDA later in 2026 to inform 2027 trial planning—suggests a longer path to market than implied by optimistic projections, with typical AIDP/PIDD studies requiring approximately 18 months to complete, meaning SG-01 is unlikely to contribute meaningfully to revenue before 2029 at the earliest, making it a distant catalyst that does not justify near-term valuation multiples.
ADMA’s gross margin expansion to 71% in Q1 2026, while impressive, is partly driven by the revenue mix shift toward higher-margin ASCENIV and cost savings from plasma center monetizations, which are one-time in nature; sustained margin expansion will depend on continued ASCENIV growth and yield enhancement benefits, but if BIVIGAM underperformance persists or if ASCENIV faces unexpected pricing pressure—despite management’s confidence in its insulation—the company may struggle to maintain margin momentum, particularly as operating expenses are expected to step up due to R&D spend on SG-01 and SG&A investments in commercial operations, potentially pressuring adjusted net income growth despite strong cash flow generation.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password